User: Guest  Login
Title:

Claudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms.

Document type:
Journal Article
Author(s):
Wöll, S; Schlitter, AM; Dhaene, K; Roller, M; Esposito, I; Sahin, U; Tureci, O
Abstract:
The majority of pancreatic neoplasms are characterized by a generally lethal progress within a short period of time after primary diagnosis and the mortality of patients is expected to increase further. Due to lack of efficient screening programs and moderate response to treatments, novel compounds for treatment are needed. We investigated the CLDN18.2 expression in affected patients as in vitro feasibility study for a potential treatment with the novel antibody IMAB362. Therefore, we analyzed t...     »
Journal title abbreviation:
Int J Cancer
Year:
2014
Journal volume:
134
Journal issue:
3
Pages contribution:
731-9
Language:
eng
Fulltext / DOI:
doi:10.1002/ijc.28400
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/23900716
Print-ISSN:
0020-7136
TUM Institution:
Institut für Allgemeine Pathologie und Pathologische Anatomie
 BibTeX